美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

294.51

+3.041.04%

盘前：307.0012.49+4.24%04:33 EDT

成交量：40.44万

成交额：1.20亿

市值：349.44亿

市盈率：-79.53

高：299.90

开：299.00

低：294.39

收：291.47

数据加载中...

总览公司新闻公告

正大天晴 HER2 双抗首次启动 III 期临床

Insight数据库

百济神州(06160)根据2016期权及激励计划授出合共4.38万股受限制股份单位

官宣了！单国洪加入百济神州

管线大爆发！百济神州血液瘤“三驾马车”成型，实体瘤8大POC蓄势，构建全球化新范式

百济神州7月2日成交额为8588.44万美元

中国药品研发实力排行榜如何解码医药行业价值投资密码？

中证500医药卫生指数下跌1.0%，前十大权重包含百济神州等

百济神州7月1日成交额为8478.41万美元

【深度拆解】创新药：医保红利+出海狂飙，谁将主宰万亿赛道？

新事丨五家CXO公司，被剔除出创新药指数

单国洪即将加入百济神州向吴晓滨汇报

南方财经网

百济神州6月30日成交额为9745.38万美元

中金：维持百济神州(06160)“跑赢行业”评级目标价198港元

中国创新药5个月对外授权455亿美元，百济神州泽布替尼全球销售13亿美元！

中国创新药能否持续让世界买单？券商分析师最新观点

百济神州：开创性肿瘤平台行业标准制定者

中国国际金融股...

8家药企去年人均薪酬超过50万，包括百济神州、迪哲医药等

百济神州的“创新超级乘法”

Ofweek维科网

BGB-43395：在既往三线治疗的乳腺癌及实体瘤患者具初步疗效和良好安全性

百济神州的新时代

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":294.51,"timestamp":1753732800000,"preClose":291.47,"halted":0,"volume":404449,"hourTrading":{"tag":"盘前","latestPrice":307,"preClose":294.51,"latestTime":"04:33 EDT","volume":392,"amount":120577.49088,"timestamp":1753778035801},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"盘前交易","change":3.04,"latestTime":"07-29 04:35:09 EDT","open":299,"high":299.9,"low":294.39,"amount":120082566.34090002,"amplitude":0.018904,"askPrice":308,"askSize":1,"bidPrice":306.3,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753795800000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":294.51,"preHourTrading":{"tag":"盘前","latestPrice":307,"preClose":294.51,"latestTime":"04:33 EDT","volume":392,"amount":120577.49088,"timestamp":1753778035801},"postHourTrading":{"tag":"盘后","latestPrice":294.51,"preClose":294.51,"latestTime":"19:50 EDT","volume":3320,"amount":977767.59,"timestamp":1753746639095},"volumeRatio":1.4511942554235662,"impliedVol":0.4413,"impliedVolPercentile":0.6596},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.4511942554235662,"shares":118650120,"dividePrice":0,"high":299.9,"amplitude":0.018904,"preClose":291.47,"low":294.39,"week52Low":155.75,"pbRate":"9.99","psRate":"8.37","week52High":300,"institutionHeld":0,"latestPrice":294.51,"committee":0.960784,"eps":-3.70325,"divideRate":0,"volume":404449,"delay":0,"ttmEps":-3.70325,"open":299,"prevYearClose":184.71,"prevWeekClose":291.47,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":291.93,"twentyDayClose":241.2,"sixtyDayClose":259.81,"earningDate":1754409600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548693336","title":"正大天晴 HER2 双抗首次启动 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2548693336","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548693336?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 08:04","pubTimestamp":1751587443,"startTime":"0","endTime":"0","summary":"近日，正大天晴在ClinicalTrials.gov 官网上登记了一项TQB2930 用于HER2 阳性乳腺癌的 III 期临床试验。公开资料显示，这是该药启动的首个III 期。2025 年 ASCO 大会上公布的是该试验中队列 4 的数据，旨在评估 TQB2930 联合化疗对至少接受过两线治疗的 HER2 阳性乳腺癌患者的安全性和有效性。截至 2024 年 12 月 15 日，已有 55 例患者接受了 TQB2930 联合化疗治疗。除此之外，正大天晴TQB2930 和康宁杰瑞/石药集团Anbenitamab-KN-026 已进入 III 期临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704080948a4ce2d9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704080948a4ce2d9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK0239","688235"],"gpt_icon":0},{"id":"2548743878","title":"百济神州(06160)根据2016期权及激励计划授出合共4.38万股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2548743878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548743878?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 16:56","pubTimestamp":1751532966,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年6月30日，董事会薪酬委员会根据2016期权及激励计划的条款授予216名承授人合共4.38万股美国存托股份受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","BK1161","BK1588","LU2328871848.SGD","LU0307460666.USD","BK4526","LU0588546209.SGD","BK1500","BK4139","688235","BK0239","BK1583","LU1969619763.USD","06160"],"gpt_icon":0},{"id":"2548878854","title":"官宣了！单国洪加入百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2548878854","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548878854?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 15:00","pubTimestamp":1751526058,"startTime":"0","endTime":"0","summary":"武田中国前总裁单国洪8月加盟百济神州，执掌大中华区及中亚南亚业务，加速跨国药企新兴市场布局。多家自媒体消息显示，原武田制药全球高级副总裁、中国区总裁单国洪将于2025年8月18日正式加入百济神州，担任大中华区及中亚、南亚区域总经理，届时将向吴晓滨博士汇报工作。6月17日上午，武田全球生物制药及国际市场业务集团总裁施睿娜向内部员工宣布了单国洪的人事变动：其决定离开武田，寻求外部发展机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703150859a72c1985&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703150859a72c1985&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139","06160","688235"],"gpt_icon":0},{"id":"2548829202","title":"管线大爆发！百济神州血液瘤“三驾马车”成型，实体瘤8大POC蓄势，构建全球化新范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2548829202","media":"药时代","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548829202?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 12:44","pubTimestamp":1751517855,"startTime":"0","endTime":"0","summary":"泽布替尼只是开始，百济神州血液瘤的上市产品格局即将焕新，新王牌索托克拉已在华申报上市，并预计在今年下半年推进全球申报。基于这些积极结果，百济神州已开启3项头对头全球III期临床。百济神州在实体瘤的故事由替雷利珠单抗领衔讲述。基于此，百济神州将在今年Q3开放乳腺癌和妇科恶性肿瘤的肿瘤特异性扩展队列，以进一步确认BG-C9074在B7-H4高表达肿瘤患者中的疗效和安全性。在肺癌领域，百济神州正在打造行业领先的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703125051a4cc84b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703125051a4cc84b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4526","ONC","BK4139","06160"],"gpt_icon":0},{"id":"2548829200","title":"百济神州7月2日成交额为8588.44万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548829200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548829200?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 12:39","pubTimestamp":1751517578,"startTime":"0","endTime":"0","summary":"美东时间2025年7月2日，百济神州成交额为8588.44万美元，成交额较昨日增加1.30%，当日成交量为35.32万股。百济神州于2025年7月2日跌0.34%，报244.32美元，该股过去5个交易日跌8.54%，年初至今涨32.27%，过去60日涨2.44%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703123944a4cc81c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703123944a4cc81c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2548847204","title":"中国药品研发实力排行榜如何解码医药行业价值投资密码？","url":"https://stock-news.laohu8.com/highlight/detail?id=2548847204","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548847204?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 09:44","pubTimestamp":1751507096,"startTime":"0","endTime":"0","summary":"2016年9月24日，《中国药品研发实力排行榜》首次发布，并在之后每年持续更新，期间始终以药企“创新属性”为核心，通过“量化研发实力”的方式精准、直接的反映出“药企成长潜力”，是医药行业投资极具价值的参照物。2025年6月20日，最新一版《中国药品研发实力排行榜》已成功发布，新一年投资机会已经更新，还不赶紧看看。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703094829a4cc3244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703094829a4cc3244&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","06160","BK0239","ONC","688235","03692","01801"],"gpt_icon":0},{"id":"2548981654","title":"中证500医药卫生指数下跌1.0%，前十大权重包含百济神州等","url":"https://stock-news.laohu8.com/highlight/detail?id=2548981654","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548981654?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 23:16","pubTimestamp":1751469403,"startTime":"0","endTime":"0","summary":"金融界7月2日消息，上证指数高开震荡，中证500医药卫生指数 下跌1.0%，报10145.27点，成交额159.01亿元。数据统计显示，中证500医药卫生指数近一个月上涨1.14%，近三个月上涨1.16%，年至今上涨5.50%。从中证500医药卫生指数持仓样本的行业来看，医药卫生占比100.00%。在样本公司有特殊事件发生，导致其行业归属发生变更时，将对中证500行业指数样本进行相应调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/02231651451531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688235","000905.SH","BK0239","BK1500","LU1969619763.USD","399905","BK1583","BK1588","BK4139","BK4526","LU2328871848.SGD","06160","159982","000001.SH","BK1161","ONC","LU0588546209.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2548953859","title":"百济神州7月1日成交额为8478.41万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548953859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548953859?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 12:29","pubTimestamp":1751430587,"startTime":"0","endTime":"0","summary":"美东时间2025年7月1日，百济神州成交额为8478.41万美元，成交额较昨日减少13.00%，当日成交量为34.74万股。百济神州于2025年7月1日涨1.28%，报245.16美元，该股过去5个交易日跌8.11%，年初至今涨32.73%，过去60日跌7.25%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702122950a729bdd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702122950a729bdd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2548833346","title":"【深度拆解】创新药：医保红利+出海狂飙，谁将主宰万亿赛道？","url":"https://stock-news.laohu8.com/highlight/detail?id=2548833346","media":"财经早餐","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548833346?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 06:34","pubTimestamp":1751409291,"startTime":"0","endTime":"0","summary":"一支抗癌药，从实验室到患者手中，需要10年、20亿美金——但中国药企正将这场“生死竞速”缩短至5年。当医保“超级买单人”砸下4100亿，海外巨头疯抢中国Biotech管线时，我们是否站在了创新药产业的历史性拐点？中国创新药产业已进入“政策驱动型增长”新阶段。核心数据印证：医保基金累计支付谈判药品4100亿元，直接撬动6000亿销售规模。当中国药企在ASCO的演讲台上与默沙东同台竞技时，资本市场需要重新定价“中国创新”的全球价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702063831a4c9adc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702063831a4c9adc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","ONC","06978","06160","01801","LU1969619763.USD","LU2328871848.SGD","BK1583","688235","BK1589","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2548000672","title":"新事丨五家CXO公司，被剔除出创新药指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2548000672","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548000672?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 22:28","pubTimestamp":1751380123,"startTime":"0","endTime":"0","summary":"6月30日，恒生港股通创新药指数宣布修订编制方案，明确剔除CXO公司，聚焦创新药核心公司。根据新的编制方案，药明生物、药明康德、金斯瑞、药明合联、晶泰控股5家公司，将从恒生港股通创新药指数中剔除。截至6月30日，恒生港股通创新药精选指数上半年涨幅达到58.95%。修订后，恒生港股通创新药指数前五大成分股，分别是信达生物、百济神州、康方生物、石药集团、中国生物制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701223315a4c9336d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701223315a4c9336d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","02228","BK4139","CXO","BK4526"],"gpt_icon":0},{"id":"2548022919","title":"单国洪即将加入百济神州 向吴晓滨汇报","url":"https://stock-news.laohu8.com/highlight/detail?id=2548022919","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548022919?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 14:13","pubTimestamp":1751350433,"startTime":"0","endTime":"0","summary":"南方财经7月1日电，原武田制药全球高级副总裁、武田中国总裁单国洪(SeanShan)将于2025年8月18日加入百济神州，出任大中华区、中亚和南亚区域总经理，并向吴晓滨汇报。单国洪将主导百济神州在大中华区、中亚和南亚这一关键增长区域的运营与战略发展，同时还将推进构建高效协同的区域运营模式，最大程度响应患者需求，助力公司全球化战略的深入实施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507013445012475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4526","LU0307460666.USD","BK1583","BK4139","LU0588546209.SGD","LU1969619763.USD","02197","BK1161","BK1588","06160","ONC","LU2328871848.SGD","BK1500"],"gpt_icon":0},{"id":"2548026060","title":"百济神州6月30日成交额为9745.38万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548026060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548026060?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 12:14","pubTimestamp":1751343249,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日，百济神州成交额为9745.38万美元，成交额较昨日增加0.53%，当日成交量为40.21万股。百济神州于2025年6月30日涨0.36%，报242.07美元，该股过去5个交易日跌6.0%，年初至今涨31.05%，过去60日跌11.9%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2548042228","title":"中金：维持百济神州(06160)“跑赢行业”评级 目标价198港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548042228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548042228?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 09:19","pubTimestamp":1751332770,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持百济神州2025年和2026年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持A/H/US股目标价280元/198港元/332美元。6月26日，公司在投资者研发日活动中，展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。公司继续沿用了百悦泽的成功开发经验，多管线并行创新，唯优质分子推向临床，这也是这些新分子在临床前就展示了BIC潜力的原因之一。另外IRAK4 CDAC半衰期优秀，计划于2H25启动II期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2548104668","title":"中国创新药5个月对外授权455亿美元，百济神州泽布替尼全球销售13亿美元！","url":"https://stock-news.laohu8.com/highlight/detail?id=2548104668","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548104668?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 06:53","pubTimestamp":1751324002,"startTime":"0","endTime":"0","summary":"2025年前五个月，国内创新药企对外授权交易总金额已达455亿美元，超越2024年上半年交易总额。百济神州缔造了中国药企首个十亿美元重磅药泽布替尼，该药于2019年在美国FDA首次获批上市，2023年全球销售额达13亿美元。2024年百济神州实现收入38亿美元，核心产品泽布替尼贡献收入26亿美元，推动公司亏损额持续收窄。这一突破标志着中国创新药在全球医药创新格局中地位的提升。商业化成果显著中国创新药企业对外授权交易金额屡创新高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/01065351396453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK4139","159992","BK1583","BK0239","BK1574","06160","06978","BK1588","LU0588546209.SGD","LU2328871848.SGD","ONC","BK4526","BK1500","688235","LU1969619763.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2547015164","title":"中国创新药能否持续让世界买单？券商分析师最新观点","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547015164?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计，2025年1—5月，中国创新药企对外授权交易总金额已达455亿美元，超过2024年上半年的交易总额，创新药出海授权交易大爆发。亮眼数据的背后，是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力，正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期，年内大涨明显的创新药企业荣昌生物股价近期大幅回调，从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688181","159992","600998","603716","600867","688068","688506","688488","688317","688166","688117","ONC","600332","688189","600080","600056","688321","688356","688136","600682","688198","603567","688202","688177","600079","688513","688091","688331","688319","601607","600645","688520","688222","600557","600267","603367","600276","688073","688235","688131","600380","600572","603456","600774","603590","603087","600216","600851","603707","600196","600422","600062","600881","688278","BK0239","600351","688505","603127","688163","06160","603259","600521","600789","600200","600222","600721","601089","603229","603998","600420","600535","688336","600513","605199"],"gpt_icon":0},{"id":"2547096481","title":"百济神州：开创性肿瘤平台 行业标准制定者","url":"https://stock-news.laohu8.com/highlight/detail?id=2547096481","media":"中国国际金融股...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547096481?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 19:48","pubTimestamp":1751284087,"startTime":"0","endTime":"0","summary":"公司近况6 月26 日，公司在投资者研发日活动中，展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。公司继续沿用了百悦泽的成功开发经验，多管线并行创新，唯优质分子推向临床，这也是这些新分子在临床前就展示了BIC潜力的原因之一。另外IRAK4 CDAC半衰期优秀，计划于2H25 启动II期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019481197948d97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019481197948d97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","688235","BK4526","06160","ONC"],"gpt_icon":0},{"id":"2547531310","title":"8家药企去年人均薪酬超过50万，包括百济神州、迪哲医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2547531310","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547531310?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 12:07","pubTimestamp":1751256420,"startTime":"0","endTime":"0","summary":"根据2024年财报，8家药企人均薪酬超过50万元，其中百济神州以90.48万元位居榜首，员工人数达1.1万人。百济神州不仅在血液学领域有显著进展，还在实体瘤领域拓展了多元管线。迪哲医药人均薪酬68.67万元，其两款产品舒沃替尼和戈利昔替尼已在中国获批上市，并带动公司营收大幅增长。亚虹医药、益方生物、盟科药业、艾力斯、福瑞股份、诺诚健华的人均薪酬分别为62.74万元、61.91万元、56.4万元、55.36万元、53.66万元、52.82万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063012131297941cff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063012131297941cff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4139","688192","ONC","BK4526"],"gpt_icon":0},{"id":"2547740039","title":"百济神州的“创新超级乘法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2547740039","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547740039?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 09:27","pubTimestamp":1751246828,"startTime":"0","endTime":"0","summary":"百济神州的研发效率极高。着眼未来，百济神州仍计划保持这种快速验证的势头。这种管线的广度、深度及推进速度，无疑是其“创新超级乘法”最直观的体现。巩固血液瘤基本盘的同时，百济神州进军高发实体瘤领域，布局多样化且差异化的新分子。“专注”之外，百济神州提升确定性的另一关键策略是积极拓展“联合疗法”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300928009793f2a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300928009793f2a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","ONC","LU0307460666.USD","688235","LU1969619763.USD","BK1500","LU0588546209.SGD","06160","BK1588","BK1161","BK1583"],"gpt_icon":0},{"id":"2547005844","title":"BGB-43395：在既往三线治疗的乳腺癌及实体瘤患者具初步疗效和良好安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2547005844","media":"山西证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547005844?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 00:00","pubTimestamp":1751212800,"startTime":"0","endTime":"0","summary":"BGB-43395 是CDK4 的高度选择性抑制剂，靶向控制细胞分裂的检查点蛋白以阻止癌细胞生长。BGB-43395具有潜在同类最佳血液学安全性特征，在既往接受过多线治疗的CDK4/6 经治患者中临床治疗有效。BGB-43395 剂量优化后安全性良好，血液毒性发生率低。BGB-43395 与氟维司群联用在实体瘤患者中观察到初步抗肿瘤活性。BGB-43395+氟维司群剂量递增给药后，37 例可评价实体瘤患者的ORR 为15%，其中19 例可评价乳腺癌患者的ORR 为11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630115118a72524a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630115118a72524a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK0239","06160"],"gpt_icon":0},{"id":"2547085826","title":"百济神州的新时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2547085826","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547085826?lang=zh_cn&edition=fundamental","pubTime":"2025-06-29 16:37","pubTimestamp":1751186273,"startTime":"0","endTime":"0","summary":"继首季度盈利之后，近日举办的投资者研发日活动让百济神州又一次站在聚光灯下。泽布替尼只是开始，百济神州血液瘤的上市产品格局即将焕新，新王牌索托克拉已在华申报上市，并预计在今年下半年推进全球申报。基于此，百济神州将在今年Q3开放乳腺癌和妇科恶性肿瘤的肿瘤特异性扩展队列，以进一步确认BG-C9074在B7-H4高表达肿瘤患者中的疗效和安全性。在肺癌领域，百济神州正在打造行业领先的产品组合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","LU2328871848.SGD","ONC","LU0588546209.SGD","BK1500","LU0307460666.USD","06160","BK1583","LU1969619763.USD","BK1161","BK1588"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":5,"totalSize":165,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748491200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-28","current":-88.139519,"percent":0.020619,"low":-89.808695,"twenty":-48.706479,"median":-39.743509,"eighty":-23.201674,"high":-19.234246,"avg":-41.250719,"sd":19.489835,"marketCap":34582950476},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-07-28","current":-88.139519,"twenty":-48.706479,"median":-39.743509,"eighty":-23.201674,"marketCap":34582950476}],"updateTime":1753778109574}}}